NEW YORK (GenomeWeb News) – Pressure BioSciences said in a regulatory document on Tuesday that it has entered into a securities purchase agreement, raising a little more than $1.2 million.

Pressure Bio entered into the agreement on Jan. 29 with various accredited investors to sell them an aggregate of 4,875 units at $250 per unit, the company said in a document filed with the US Securities and Exchange Commission. Purchasers included existing and new investors in the company and members of its board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.